The reality is, why stretch out a trial? To get 5,7, and perhaps 10 year OS data. I am certain they did not plan this originally, but when they realized how good DCVAX can be, it makes sense. Good luck to competition running a trial long enough to get the long OS data.
Most biotechs fail, they follow the same strategy. A path never traveled is always GROUNDBREAKING... and your get GROUNDBREAKING results.